Overview

Cetuximab for Elderly Patients With mCRC

Status:
Terminated

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

OBJECTIVE: The objective of the trial is to judge on the benefit obtained by an upfront cetuximab treatment delivered as monotherapy or as part of a combination treatment with capecitabine in vulnerable elderly patients selected for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type and B-type Raf kinase (BRAF) wild-type metastatic colorectal cancer (mCRC).

Phase:

Phase 2

Details

Lead Sponsor:

Swiss Group for Clinical Cancer Research

Treatments:

Capecitabine
Cetuximab